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Abstract
Background: The prevalence of depression increases among the elderly with chronic medical
conditions like diabetes. Hence, the purpose of this study was to determine predictors of
depressive symptomatology in Medicare enrolled elderly population with type 2 diabetes mellitus.
Methods: A prospective cohort study was conducted by administrating health risk assessment
questionnaire to elderly (≥65 years) with type 2 diabetes. Responses were linked with
administrative claim's data. Data were obtained from elderly with type 2 diabetes who were
enrolled in Medicare Health Maintenance Organization (HMO) in southeastern United States. The
instrument collected information related to demographics, health status, medication use, and
healthcare service utilization prior to enrollment. Responses were combined with the
administrative claims data of HMO to obtain information on actual utilization of healthcare
resources. The Short Form Center for Epidemiologic Studies Depression scale was used to assess
depressive symptoms. Multivariable logistic regression analyses were conducted to determine
predictor variables.
Results: Of 792 respondents, about 17% had depressive symptoms. Almost 96% of patients were
using 1 or more antidiabetic medications. Overall, increased risk of depression was associated with
lower health related quality of life (HRQoL) (OR: 0.97; 95% CI: 0.96–0.98) and higher impairments
in instrumental activities of daily living (IADLs) (OR: 1.31; 95% CI: 1.14–0.52) in elderly patients.
Poor health related quality of life (OR: 0.97, 95%CI: 0.95–0.99) was associated with higher risk of
depression in patients on insulin therapy.
Conclusion: Impairments in daily activities and lower HRQoL were predictors of depressive
symptomatology in elderly with diabetes. Determinants of depression varied according to
pharmacotherapeutic class of antidiabetic medications.
Background
Diabetes affects 20.8 million individuals and is consid-
ered as the sixth leading cause of death in the United
States [1]. It poses an immense economic burden on the
U.S. healthcare system costing around $100 billion annu-
ally [1]. Around 7 million elderly Americans suffer from
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type 2 diabetes mellitus. An elderly population in the
United States is associated with maximum utilization of
healthcare resources [2].
Like diabetes, depression is growing concern in the United
States afflicting around 19 million Americans annually
[3]. Of the 35 million Americans of age 65 and older, an
estimated two million suffer from depression [4]. The
prevalence of depression further increases among the eld-
erly with chronic medical conditions like diabetes. The
odds of depression in patients with diabetes are twofold
than those without diabetes [5]. Research has reported
that approximately 30% of individuals with diabetes have
depressive symptomatology and 10% suffer from major
depression [6]. Both diabetes and depression were major
contributors of functional disability in the elderly popula-
tion [7]. Furthermore, co-morbid depression in diabetes
patients accounted for 4.5 times higher healthcare
expenditure than those without depression [8].
Several sociodemographic, clinical and behavioral factors
have been considered as determinants of depression in
diabetes patients. Studies have shown that age, gender,
education and income were significant predictors of
depression in diabetic population. [9-11] Depression has
been found to be associated with diabetes related psycho-
logical and physiological processes including diabetes
complication [12], increased blood glucose level [13], and
insulin dependence [5]. Behavioral factors such as smok-
ing and alcohol abuse were also associated with depres-
sion [14].
The impact of a type of pharmacotherapy on depressive
symptomatology in the elderly population with type 2
diabetes has not been studied yet. Patients with diabetes
are treated with oral antidiabetic medications (OADs) or
insulin or combination therapy depending upon patient
characteristics, severity of disease, glycemic level and risk
of complications [15]. The impact of pharmacotherapy
becomes a major concern in the elderly who are on poly-
pharmacy and highly vulnerable to morbidity and mortal-
ity. Hence, the type of anti-diabetic medication therapy
may have influence on the comorbid depression in sub-
group of patients. Taking into account higher prevalence
of depression among elderly, as the baby-boomer genera-
tion ages, this illness will contribute to the continued
financial strain on the health care system. Thus, the objec-
tive of this study was to identify self-reported predictors of
depressive symptomatology in the elderly with diabetes.
Methods
Study design and population
This was a prospective cohort study started in late 1996
with annual follow up for 2 years postenrollment. The
study population consisted of elderly patients (age 65
years or above) with type 2 diabetes mellitus in the south-
eastern United States who were enrolled in a Medicare
Health Maintenance Organization (HMO). This HMO
plan was a sole provider of medical care to these enrollees
("lock in" risk benefit plan). The study was conducted by
administering a health status assessment questionnaire to
nearly 1000 enrollees. The subjects enrolled in Medicare
HMO were selected randomly for the purpose of this
study and questionnaire was sent to them.
The study was restricted to elderly with type 2 diabetes
using some type of pharmacotherapy for diabetes man-
agement. The subjects were identified using the codes for
type 2 diabetes mellitus (250.xx) from the International
Classification of Diseases, Ninth Revision, Clinical Modi-
fication (ICD-9-CM) [16] and the HMO's internal medi-
cation coding system for prescribing antidiabetic
medications.
The survey questionnaires were mailed to participants and
informed consent was obtained from them. Participation
in this study was voluntary and data were kept confiden-
tial. The data were made available to researchers by the
Medicare HMO after removal of all patient identifiers. The
response rate for the survey was 80%. The questionnaires
which provided responses for more than 80% of the items
in the study were included in the analysis. All question-
naires were usable. Questionnaire in which depression
measure was not reported or incomplete were evaluated
for the pattern of missing data. The missing data was ran-
dom and hence those questionnaires were not included in
the study. The study protocol was reviewed and approved
by the Institutional Review Board at Wake Forest Univer-
sity School of Medicine for data collection from human
subjects. The responses obtained from questionnaire were
combined with actual 2-year postenrollment claims data.
Measurements
The health status assessment instrument collected infor-
mation regarding demographics, general health status,
sedentary lifestyle, functional status, depression, health
related quality of life and health care service utilization in
preenrollment year. The responses to questionnaire
formed basis for the demographic, health status and
healthcare utilization variables. The demographic varia-
bles were age, gender and whether enrollee lived alone.
The health status variables were indicators of sedentary
status (from questions examining physical activity and
whether the enrollee walked for at least 30 minutes per
week), smoking status (i.e. more than 10 cigarettes per
day was considered as a heavy smoker) alcohol consump-
tion (i.e. more than 3 drinks per day was considered as a
heavy alcohol drinker) and perceived general health status
(whether the patient perceived that health status wors-
ened during the year preceding enrollment). FunctionalHealth and Quality of Life Outcomes 2007, 5:50 http://www.hqlo.com/content/5/1/50
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status of enrollees was assessed by impairments in the
number of activities of daily living (ADLs) (e.g. eating,
dressing, taking bath etc.) and the number of instrumen-
tal activities of daily living (IADLs) (e.g shopping for gro-
cery, preparing meals etc).
The Medical Outcomes Study Short Form 12 (SF-12) was
used to determine health related quality of life (HRQoL)
[17]. The Short Form Center for Epidemiologic Studies
Depression (CES-D) scale was used to measure depression
(dependent variable) on the scale of 0 to 60 [18]. The
score of 16 or higher on CES-D was considered as a posi-
tive response for depressive symptoms. Funcational sta-
tus, HRQoL and depression were measured for
preenrollment year. Healthcare utilization variables were
self-reported prescription medications, physician office
visits, emergency room (ER) visits and hospitalizations in
the year prior to plan enrollment.
The administrative claims data of patients' HMO was used
to retrieve information about actual utilization of health-
care resources during the 2 year postenrollment follow up
period. The information obtained was a type of pharma-
cotherapy, and prescription refills. Responses obtained
from survey were combined with actual claim's data
acquired from HMO.
Statistical analysis
Descriptive analyses were performed to evaluate patterns
of antidiabetic medication use. Chi square statistics were
used to determine differences in categorical variables of
diabetic patients with and without depression. An inde-
pendent sample t test was used for continuous measures.
Data were analyzed using STATA statistical package (ver-
sion 9.1) at a set priori significance level of 0.05.
Multivariate logistic regression model was used to exam-
ine associations between predictor variables (as captured
by health status assessment questionnaire) and risk of
depression. The main model consisted of following pre-
dictor variables which are listed as follows: demographics
variable consisted of age, gender, health status variables
included number of prescriptions, antidiabetic medica-
tion use, perceived health status, health related quality of
life and self-reported healthcare utilization variables
incorporated number of hospitalizations and ER visits in
preenrollment year. The regressions were tested for the
presence of multicollinearity (ie linear relationship
among predictor variables). All correlation coefficients
between the predictor variables were less than 0.4 and var-
iation inflation factor of 2 indicated the absence of multi-
collinearity. Subgroup analyses were performed to
identify risk factors of depression in patients with differ-
ent types of pharmacotherapy.
Results
The sample consisted of 792 elderly patients with type 2
diabetes mellitus. Almost 60% of the participants were
women and mean age of subjects was 71 (± 8.7) years. Of
the 792 respondents, about 17% had depressive symp-
tomatology. Most of them (96.7%) were using 1 or more
antidiabetic medications. The pharmacotherapy com-
prised of oral antidiabetic medications, insulin or combi-
nation.
Table 1: Summary of descriptive characteristics of the elderly population with type 2 diabetes mellitus and enrolled in a Medicare 
health maintenance organization
Characteristic Total 
(n = 792)
With depression 
(n = 137)
Without depression 
(n = 655)
Test statistics 
(p value)
Age (years), mean (SD) 71. 95 (8.7) 69.42 (11.33) 72.47 (7.92) 6.3486 (0.000)
Sex (% male) 43.97 39.71 44.87 4.48 (0.034)
Current smokers (%) 12.5 14.59 12.1 2.73 (0.099)
Any alcohol consumption (%) 5.55 3.65 5.95 2.24 (0.134)
Physically active (%) 26.64 16.79 28.70 17.91 (0.000)
SF-12 general health score, mean (SD) 46.09 (25.25) 30.58 (21.82) 49.37 (24.71) 91.29 (0.000)
No of ADLs causing problems, mean (SD) 0.37 (1.07) 0.81 (1.52) 0.28 (0.92) 67.96 (0.000)
No of IADLs causing problems, mean, (SD) 0.97 (1.72) 2.04 (2.24) 0.75 (1.50) 105.05 (0.000)
Prescription refills mean (SD) 3.33 (0.98) 3.62 (0.75) 3.26 (1.01) 0.25 (0.615)
Antidiabetic medication use (%) 99.62 98.54 99.84 0.99 (0.319)
Hospitalization during previous year (%) 29.67 48.9 25.65 25.88 (0.000)
ER visits during previous year (%) 38.28 67.91 32.15 34.91 (0.000)
SF-12 = Medical Outcomes Study 12-item Short Form Health Survey; ADLs = Activities of Daily Living; IADLs = Instrumental Activities of Daily 
Living; ER = Emergency room.
Independent sample t test was performed for continuous variables such as age, SF-12 scores, No of ADLs causing problems, No of IADLs causing 
problems, and prescription refills.
Chi2 test of independence was performed for sex, current smoker, any alcohol consumption, physical activities, hospitalization in previous year and 
ER visits in previous yearHealth and Quality of Life Outcomes 2007, 5:50 http://www.hqlo.com/content/5/1/50
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Table 1 compares characteristics of individuals with dia-
betes by depression status. It was found that elderly with
depression were mostly of age 70 years and women com-
pared with those without depression (p < 0.05). Patients
with depression were more likely to have sedentary life-
style, poorer general health status, higher impairment in
activities of daily living, and lower health related quality
of life compared to those without depression (p < 0.05).
The elderly with co-morbid depression experienced signif-
icantly more number of self-reported hospitalizations and
emergency room visits in previous year compared to no
depression group (p < 0.05). Subgroup analysis con-
ducted to evaluate the patterns of anti-diabetic medica-
tion use indicated that most of the patients (80%) were
predominantly using oral antidiabetic medications.
Table 2 shows the results of multivariate logistic regres-
sion examining predictors of depressive symptomatology.
Age was a significant predictor but weakly associated with
risk of depression (OR: 0.97; 95% CI: 0.94–0.99). Patients
with lower health related quality of life were significantly
associated with higher risk of depression (OR: 0.97; 95%
CI: 0.96–0.98). Likelihood of depression increased by
31% with higher impairments in instrumental activities of
daily living (IADLs) (OR: 1.31; 95% CI: 1.14–0.52).
Table 2 also summarizes the effect of type of antidiabetic
therapy on risk of depression. When categorized by phar-
macotherapeutic class of antidiabetic medications, poor
health related quality of life (OR: 0.97, 95%CI: 0.95–
0.99) was associated with higher risk of depression in
patients on insulin therapy. Similarly, the odds of depres-
sion increases with increased impairments in IADLs. (OR:
1.24, 95%CI: 1.01–1.53) in patients on insulin therapy.
However, in patients on sulfonylurea, males were less
likely to be at a risk of depression than females (OR: 0.48,
95%CL: 0.28–0.82). Likelihood of depression was associ-
ated with self-reported hospitalization (OR: 0.55, 95%CI:
0.34–0.88), and emergency room visits in previous year
(OR: 1.45, 95%CI: 1.01–2.08). The odds of depression
increases with lower health related quality of life (OR:
0.97, 95%CI: 0.96–0.98) and with increased impairments
in IADLs (OR: 1.29, 95%CI: 1.07–1.56) in patients on sul-
fonylurea therapy. When patients on combination ther-
apy were examined, likelihood of depression was
associated with lower health related quality of life (OR:
0.95, 95%CI: 0.91–0.99).
Discussion
This study revealed that co-morbid depression in elderly
with diabetes was associated with younger age, lower
health related quality of life and higher impairment in
instrumental activities of daily living. Our findings are
consistent with the existing literature [19-24]. SF-12 could
be used as an effective tool to detect depression and dem-
onstrate health related quality of life in diabetic patients
with depression. The Diabetes-Specific Quality of Life
Scale will be also helpful to measure depression in these
patients. Periodical assessment of patients' health related
quality of life can give an early opportunity to health care
professionals and hospital administrators to identify
patients at higher risk of depression and refer them to
proper disease risk management program. Similarly, the
odds of depressive symptoms were significantly high in
the elderly with higher impairment in instrumental activ-
ities of daily living. IADL limitations are also attributed to
Table 2: Predictors of depression in the elderly population with type 2 diabetes mellitus and enrolled in a Medicare health maintenance 
organization
Depressive symptomatology
Independent variables Sample 
(n = 792)
Only insulin 
(n = 252)
Only sulfonylurea 
(n = 562)
Combination therapy 
(n = 71)
Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
Age (years) 0.97 (0.94–0.99)* 0.97 (0.94–1.1) 0.97 (0.95–1.00) 0.99 (0.92–1.06)
Male gender 0.67 (.43–1.05) 0.99 (0.47–2.1) 0.48 (0.28–0.82)* 0.62 (0.16–2.36)
Health related quality of life 0.97 (0.96–0.98)* 0.97 (0.95–0.99)* 0.97 (0.96–0.98)* 0.95 (0.91–0.99)*
ADLs causing problems 0.87 (0.71–1.1) 0.83 (0.59–1.12) 0.83 (0.61–1.15) 0.64 (0.23–1.71)
IADLs causing problems 1.31 (1.14–0.52)* 1.24 (1.01–1.53)* 1.29 (1.07–1.56)* 1.31(0.82–2.08)
No of Prescription 1.02 (0.77–1.35) 2.06 (0.90–4.72) 0.91 (0.68–1.23) 0.79 (0.23–2.71)
Hospitalizations during previous year 0.93 (.64–1.28) 1.28 (0.80–2.05) 0.58 (0.35–0.95)* 0.81 (0.31–2.08)
ER visits during previous year 1.22 (0.90–1.66) 1.10 (0.68–1.78) 1.51 (1.04–2.18)* 1.06 (0.49–2.26)
Insulin therapy 0.88 (0.31–2.52) - - -
Sulfonylurea therapy 1.49 (0.55–4.03) - - -
Combination therapy 1.66 (0.54–5.12) - - -
*Statistically significant at p < 0.05.
ADLs = Activities of Daily Living; IADLs = Instrumental Activities of Daily Living; ER = Emergency room.Health and Quality of Life Outcomes 2007, 5:50 http://www.hqlo.com/content/5/1/50
Page 5 of 6
(page number not for citation purposes)
physical health related chronic conditions co-morbidity
such as diabetes [22]. The literature has documented that
impaired activities in diabetic patients can cause substan-
tial problems such as functional decline, dependency and
physical disability [7,22,23]. Hence, the functional status
of elderly with diabetes can be considered as an important
indicator for identifying patient at a risk of depression.
This study also examined the impact of prescribing phar-
macotherapy on risk of depression in diabetic patients.
Interestingly, the pharmacotherapeutic class of antidia-
betic medications has a significant impact on the risk of
depression in diabetic patients. Patients with type 2 diabe-
tes who fail to respond adequately to oral antidiabetic
medications (OADs) or whose glycemic control worsens
despite using recommended combinations of OADs often
start insulin therapy [25]. The study found that among the
patients on insulin therapy, likelihood of depression
increased with the increased impairments in IADLs.
Among the patients on insulin therapy and/or combina-
tion therapy, higher odds of depression were associated
with lower HRQoL as measured by SF-12 instrument.
When we examined elderly patients on sulfonylurea ther-
apy, likelihood of comorbid depression increases in
females compared to males. Similar to other antidiabetic
medications, the odds of depression were associated with
lower HRQoL and increased impairment in IADLs. The
odds of self reported hospitalizations were lower in
patients on sulfonylurea therapy in previous year. It may
be due to lower number of complications associated with
use of sulfonylurea in elderly patients. However, this con-
clusion can not be confirmed from the given analysis.
These findings have huge implications from public health
perspective. Monitoring patients' characteristics, anti-dia-
betic therapy and medication use patterns will facilitate
early identification of patients at risk of depression.
Patients on insulin therapy commonly face problems such
as needle anxiety, fear of injection pain, and inconven-
ience of administration, troublesome dosing schedule,
and social stigma [26-28]. Patient's psychological and
behavioral characteristics may be associated with poor
HRQoL and associated depression. Hence, clinicians
should take special efforts in educating and counseling
patients regarding appropriate use of insulin therapy. This
study also support and emphasizes an importance of
developing patient-centered pharmacotherapy to pre-
clude the problems associated with depression. It is essen-
tial for policy makers to develop special screening
guidelines for depression in a subset of patients on sulfo-
nylurea therapy. Especially female patients using sulfony-
lurea with higher frequency of ER visits should be targeted
for early screening and monitoring of depression.
The results of this study should be generalized with cau-
tion since data were obtained from single geographically
located Medicare HMO. The study could not evaluate the
effect of risk factors such as glycemic control, social sup-
port on depressive symptomatology due to lack of availa-
bility of data. Additionally, the observational study design
does not permit causal inference between diabetes and
depression.
This study strengthens the hypothesis that there is a strong
relationship between depression and diabetes. Depres-
sion may exacerbate, or alternatively be exacerbated by
diabetes. Diabetes management program can substan-
tially benefit elderly who are at risk of depression in terms
of improving health outcomes and quality of life. Taking
into account a wide variation in the treatment pattern and
its impact on comorbid depression, hospital administra-
tors should focus on patient centered pharmacotherapy,
timely screening and improving patients' health status.
Conclusion
Comorbid depression is prevalent in elderly patients with
type 2 diabetes mellitus. Patient characteristics such as
age, lower health related quality of life and impairment in
instrumental activities of daily livings were significant
determinants of depression in diabetic patients. Type of
pharmacotherapeutic class of anti-diabetic medications
has a significant impact in predicting comorbid depres-
sion in elderly population. Hence, health care profession-
als should take into consideration likelihood of comorbid
depression while prescribing pharmacotherapy for the
treatment of type 2 diabetes.
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